Summit Global Investments Purchases 11,952 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Summit Global Investments boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 154.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,704 shares of the specialty pharmaceutical company's stock after purchasing an additional 11,952 shares during the period. Summit Global Investments owned about 0.09% of ANI Pharmaceuticals worth $1,176,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millennium Management LLC raised its stake in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock worth $14,651,000 after buying an additional 209,272 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of ANI Pharmaceuticals by 149.7% in the third quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company's stock worth $11,107,000 after buying an additional 111,613 shares during the period. F M Investments LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter worth about $3,686,000. American Century Companies Inc. raised its stake in shares of ANI Pharmaceuticals by 99.2% in the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company's stock worth $6,357,000 after buying an additional 49,717 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock worth $40,132,000 after buying an additional 21,053 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Trading Up 5.2 %

Shares of ANI Pharmaceuticals stock traded up $3.06 on Friday, reaching $61.44. The company had a trading volume of 348,422 shares, compared to its average volume of 212,347. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 52.51 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The firm's 50-day moving average price is $58.66 and its two-hundred day moving average price is $61.55. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million during the quarter, compared to analysts' expectations of $129.09 million. During the same quarter in the previous year, the business earned $1.06 EPS. ANI Pharmaceuticals's revenue was up 18.5% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on ANIP shares. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an "overweight" rating and a $68.00 target price on the stock. StockNews.com downgraded ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Truist Financial lifted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. Finally, Raymond James lifted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.